Sintilimab plus a bevacizumab biosimilar (IBI305) in advanced HCC with Child-Pugh A/B liver function: a real-world multicenter retrospective study.

Front Oncol · 2025 · PMC12626817 · PMID 41267992

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0570

boldest claim

The sentences

a favorable trendp=0.050actually significant

Prior RFA was associated with a favorable trend (HR 2.410, 95% CI 1.001-5.802; p=0.050).

also in 1,335 other papers

showed a trendp=0.057so close (0.05 < p ≤ 0.1)

BCLC stage C showed a trend toward unfavorable prognosis versus stage B (HR 3.160, 95% CI 0.965-10.353; p=0.057).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Notably, any-grade bleeding was more frequent in CP-B patients (26.9% vs 11.0%; p=0.103), though this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.